[{"orgOrder":0,"company":"SynOx Therapeutics","sponsor":"Healthcaps India","pharmaFlowCategory":"D","amount":"$45.0 million","upfrontCash":"Undisclosed","newsHeadline":"SynOx Therapeutics raises \u20ac37M in Series A Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Series A Financing","leadProduct":"Emactuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"SynOx Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"SynOx Therapeutics \/ HealthCap","highestDevelopmentStatusID":"6","companyTruncated":"SynOx Ther.."},{"orgOrder":0,"company":"SynOx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emactuzumab Designated as an Orphan Medicinal Product in Europe","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Emactuzumab","moa":"CSF1R","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"SynOx Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"SynOx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"SynOx Ther.."},{"orgOrder":0,"company":"SynOx Therapeutics","sponsor":"Forbion","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"SynOx Therapeutics Announces $75m Series B Round to Fund Phase 3 Trial of Potential Best-in-class Treatment for TGCT","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Series B Financing","leadProduct":"Emactuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"SynOx Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Infusion","sponsorNew":"SynOx Therapeutics \/ Forbion","highestDevelopmentStatusID":"10","companyTruncated":"SynOx Ther.."},{"orgOrder":0,"company":"SynOx Therapeutics","sponsor":"Hercules Capital","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"SynOx Therapeutics Secures up to $35m Debt Financing with Hercules Capital to Progress Development and Commercialisation of Emactuzumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Series B Financing","leadProduct":"Emactuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"SynOx Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Infusion","sponsorNew":"SynOx Therapeutics \/ Hercules Capital","highestDevelopmentStatusID":"10","companyTruncated":"SynOx Ther.."}]

Find Clinical Drug Pipeline Developments & Deals by SynOx Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Lead Product(s) : Emactuzumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Partner/Sponsor/Collaborator : Hercules Capital

                          Deal Size : $75.0 million

                          Deal Type : Series B Financing

                          Details : The financing is intended to support the clinical development of Synox's late-stage product and the commercialization of emactuzumab for treating Tenosynovial Giant Cell Tumor.

                          Product Name : Undisclosed

                          Product Type : Large molecule

                          Upfront Cash : Undisclosed

                          April 30, 2024

                          Lead Product(s) : Emactuzumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Partner/Sponsor/Collaborator : Hercules Capital

                          Deal Size : $75.0 million

                          Deal Type : Series B Financing

                          blank

                          02

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Details : The proceeds will be used to advance late-stage product Emactuzumab, SynOx's potentially best-in-class CSF-1(R) inhibiting monoclonal antibody for the treatment of Tenosynovial Giant Cell Tumour.

                          Product Name : Undisclosed

                          Product Type : Large molecule

                          Upfront Cash : Undisclosed

                          April 22, 2024

                          Lead Product(s) : Emactuzumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Partner/Sponsor/Collaborator : Forbion

                          Deal Size : $75.0 million

                          Deal Type : Series B Financing

                          blank

                          03

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Lead Product(s) : Emactuzumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Partner/Sponsor/Collaborator : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Details : Emactuzumab is a novel monoclonal antibody inhibiting CSF-1R that offers a short course of treatment. Phase I/II studies indicated good tolerability and a manageable safety profile and substantial prelimi...

                          Product Name : Undisclosed

                          Product Type : Large molecule

                          Upfront Cash : Not Applicable

                          August 31, 2022

                          Lead Product(s) : Emactuzumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Partner/Sponsor/Collaborator : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Details : The financing will enable SynOx to continue the development of emactuzumab, for the treatment of diffuse tenosynovial giant cell tumours (“TGCT”), also known as pigmented villonodular synovitis (”PV...

                          Product Name : CXD301

                          Product Type : Large molecule

                          Upfront Cash : Undisclosed

                          November 19, 2020

                          Lead Product(s) : Emactuzumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Partner/Sponsor/Collaborator : Healthcaps India

                          Deal Size : $45.0 million

                          Deal Type : Series A Financing

                          blank